Filing Flows › Xilio Therapeutics (XLO) › Recalls, complaints & regulation
Xilio Therapeutics (XLO): clinical trials
Xilio Therapeutics (XLO) beyond its filings: 2 active clinical trials.
Xilio Therapeutics' latest quarter
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Xilio Therapeutics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.